(KRON) — The future of one biotech company on the Peninsula is drastically changing. Unity Biotechnology is laying off its entire workforce, the company announced Monday in a press release.

Unity Biotechnology, a Bay Area company that once won high-profile backers and a $700 million valuation for its research into aging, is now laying off every one of its remaining employees.

China’s WuXi AppTec, which a US legislative commission called the “Huawei equivalent for biotechnology”, has reported a surge in US business despite increased scrutiny from Washington ...

Rather, with so much uncertainty, investors are prizing biotech companies that base their intellectual property and manufacturing in the U.S., which up until now often meant higher taxes.

But today, Kendall has been reborn — as the glittering, glassy heart of America’s biotech industry. For many companies, Kendall Square’s status as a global center of biotechnology firms and ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech ...

Bay Area biotech company Tempest Therapeutics was once valued at more than $1 billion, but now it’s running out of gas. Last week, the cancer researcher revealed plans to lay off all but five ...

Earlier this week, the congressionally-mandated National Security Commission on Emerging Biotechnology released its major report, titled “Charting the Future of Biotechnology.” The bipartisan ...

The comprehensive report from the bipartisan National Security Commission on Emerging Biotechnology (NSCEB) delivers a “sobering, even frightening,” conclusion: that China is quickly ascending to ...

The AI biotech is also looking to expand its team as it grows. "This funding will further turbocharge the development of our next-generation AI drug design engine, help us advance our own programs ...

In this article, we will be taking a look at the 7 most profitable biotech stocks to buy right now. With improved market conditions, innovative breakthroughs, and more investor interest ...

Dr Liz Fletcher, director of operations and business engagement at the Industrial Biotechnology Innovation Centre (IBioIC) (Picture: Fraser Cameron) This is where the bioeconomy comes into play ...